Pterostilbene inhibits hepatocellular carcinoma proliferation and HBV replication by targeting ribonucleotide reductase M2 protein.

Rui Wang, Zhijian Xu, Jiaping Tian, Qian Liu, Jingwen Dong, Lijuan Guo, Boning Hai, Xia Liu, Hangping Yao, Zhi Chen, Junjie Xu, Lijun Zhu, Haiyi Chen, Tingjun Hou, Weiliang Zhu, Jimin ShaoPubMed 2021

TL;DR

This study identifies pterostilbene, a natural compound found in blueberries and grapes, as a potent inhibitor of ribonucleotide reductase M2 (RRM2). By targeting RRM2, pterostilbene effectively suppresses both hepatocellular carcinoma (HCC) cell proliferation and Hepatitis B virus (HBV) replication, offering a promising dual-action therapeutic strategy for HBV-related HCC.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with Hepatitis B virus (HBV) infection being a major contributing factor. Current treatments for advanced HCC are limited, and drug resistance is a significant challenge. Ribonucleotide reductase (RR), particularly its M2 subunit (RRM2), is crucial for DNA synthesis and is often overexpressed in HCC, making it a potential therapeutic target. Furthermore, HBV utilizes host cell machinery, including RRM2, for its replication. Therefore, there's a critical need for novel agents that can simultaneously combat HCC proliferation and HBV replication, especially those that can overcome existing drug resistance.

Methods

The researchers employed a multi-pronged approach:

  • Computer-Aided Screening: They used 3D structure-based virtual screening to identify potential RRM2 inhibitors from drug-like compound libraries.
  • Biochemical Assays: In vitro RR enzyme activity assays were performed to quantify the inhibitory potency of candidate compounds.
  • Fluorescence Quenching: This technique was used to study the direct binding interaction between pterostilbene and RRM2 protein.
  • Cell-Based Assays:
    • MTT Assays: Standard method to assess cell viability and determine IC50 values for anti-proliferative effects.
  • Clonogenic Assays: Evaluated the long-term colony-forming ability of cells, indicating sustained inhibition of proliferation.
  • Apoptosis Assays: Used flow cytometry (Annexin V-FITC/PI staining) to quantify programmed cell death induced by the compound.
  • EdU Incorporation Assays: Measured newly synthesized DNA to assess the impact on DNA synthesis.
  • Cell Cycle Analysis: Flow cytometry was used to determine how pterostilbene affects cell cycle progression.
  • HBV DNA Quantification: Real-time PCR (Q-PCR) was employed to measure intracellular HBV DNA levels, assessing the compound's antiviral efficacy.
  • Immunoprecipitation and HPLC/MS/MS: Used to confirm the direct binding of pterostilbene to RRM2 protein in vivo.
  • Mouse Xenograft Model: In vivo studies were conducted using nude mice bearing HCC tumors to evaluate the anti-tumor efficacy and toxicity of pterostilbene.
  • Histopathological Examination: Tissues from treated mice were analyzed to assess potential organ toxicity.

Datasets

Not explicitly discussed as distinct datasets. The study utilized established human HCC cell lines (Huh7, Hep3B, HepG2, HepG2.2.15) and a sorafenib-resistant HepG2 cell line. HBV DNA levels were quantified using Q-PCR.

Key Insights and Ideas

  • Pterostilbene as a Potent RRM2 Inhibitor: The study unequivocally demonstrates that pterostilbene directly targets and inhibits RRM2, a critical enzyme for DNA synthesis. This is a significant finding, as RRM2 is implicated in both cancer proliferation and viral replication.
  • Dual Action Against HCC and HBV: The most compelling insight is pterostilbene's ability to simultaneously inhibit HCC cell growth and HBV replication. This dual efficacy is highly desirable for treating HBV-related HCC, a complex disease.
  • Overcoming Drug Resistance: Pterostilbene showed comparable efficacy against sorafenib-resistant HCC cells and was particularly effective against lamivudine-resistant HBV strains. This suggests it could be a valuable option for patients who have developed resistance to current therapies.
  • Mechanism of Action Confirmation: The reversal of pterostilbene's effects by dNTP precursors strongly supports RRM2 as its direct intracellular target, providing a clear mechanistic understanding.
  • Favorable In Vivo Profile: The mouse xenograft studies indicate that pterostilbene can effectively reduce tumor growth with relatively low toxicity, making it a promising candidate for further clinical development.

Key Results

  • Pterostilbene inhibited in vitro recombinant RR enzyme activity with an IC50 of 0.62 µM, significantly more potent than hydroxyurea (HU) and COH29.
  • In HCC cell lines, pterostilbene exhibited anti-proliferative effects with MTT IC50 values ranging from 20-40 µM.
  • Pterostilbene induced DNA synthesis inhibition, S-phase cell cycle arrest, and apoptosis in HCC cells.
  • The compound significantly inhibited HBV DNA replication in HepG2.2.15 cells (EC50 ~4-fold lower than HCC proliferation IC50).
  • Pterostilbene showed similar anti-proliferative activity against both wild-type and sorafenib-resistant HepG2 cells.
  • It effectively inhibited both wild-type and 3TC-resistant HBV replication, with EC50 values for HBV replication being significantly lower than for host cell viability.
  • In mouse xenograft models, pterostilbene (50 and 100 mg/kg/day) significantly reduced tumor growth without causing significant changes in body weight or major organ toxicity.

Limitations and Future Work

  • In Vitro vs. In Vivo Potency: While pterostilbene showed high potency in vitro against RR, its IC50 for cell proliferation was in the micromolar range. Further optimization might be needed to achieve even higher therapeutic indices.
  • Clinical Translation: The study provides strong preclinical evidence, but human clinical trials are necessary to confirm safety and efficacy in patients.
  • Mechanism of Resistance: While pterostilbene overcomes sorafenib and lamivudine resistance, understanding the precise molecular mechanisms behind this is crucial for future drug development.
  • Combination Therapies: Exploring combinations of pterostilbene with other existing or novel therapies could potentially enhance efficacy and further mitigate resistance.
  • Further Preclinical Studies: Investigating the long-term effects and potential side effects in more diverse animal models would be beneficial.

Summary updated

Abstract

Hepatocellular carcinoma (HCC), one of the most deadly diseases all around the world. HBV infection is a causative factor of HCC and closely associated with HCC development. Ribonucleotide reductase (RR) is a key enzyme for cellular DNA synthesis and RR small subunit M2 (RRM2) is highly upregulated in HCC with poor survival rates. We have previously shown that HBV can activate the expression of RRM2 and the activity of RR enzyme for the viral DNA replication in host liver cells. Thus, RRM2 may be an important therapeutic target for HCC and HBV-related HCC. Pterostilbene, a natural plant component, potently inhibited <i>in vitro</i> RR enzyme activity with the IC<sub>50</sub> of about 0.62 μM through interacting with RRM2 protein, which was much higher than current RRM2 inhibitory drugs. Pterostilbine inhibited cell proliferation with an MTT IC<sub>50</sub> of about 20-40 μM in various HCC cell lines, causing DNA synthesis inhibition, cell cycle arrest at S phase, and accordingly apoptosis. On the other hand, the compound significantly inhibited HBV DNA replication in HBV genome integrated and newly transfected HCC cells, and the EC<sub>50</sub> for inhibiting HBV replication was significantly lower than the IC<sub>50</sub> for inhibiting HCC proliferation. Notably, pterostilbene possessed a similar inhibitory activity in sorafenib and lamivudine resistant HCC cells. Moreover, the inhibitory effects of pterostilbine against HCC proliferation and HBV replication were significantly reversed by addition of dNTP precursors, suggesting that RR was the intracellular target of the compound. Finally, pterostilbine effectively inhibited HCC xenograft growth with a relatively low toxicity in nude mouse experiments. This study demonstrates that pterostilbene is a novel potent RR inhibitor by targeting RRM2. It can simultaneously inhibit HCC proliferation and HBV replication with a potential new use for treatment of HCC and HBV-related HCC.
BibTeX
@inproceedings{wang2021pterostilbene,
  author = {Rui Wang and Zhijian Xu and Jiaping Tian and Qian Liu and Jingwen Dong and Lijuan Guo and Boning Hai and Xia Liu and Hangping Yao and Zhi Chen and Junjie Xu and Lijun Zhu and Haiyi Chen and Tingjun Hou and Weiliang Zhu and Jimin Shao},
  title = {{Pterostilbene inhibits hepatocellular carcinoma proliferation and HBV replication by targeting ribonucleotide reductase M2 protein.}},
  booktitle = {PubMed},
  year = {2021},
}
Figure